Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Phexxi on the Vaginal Microbiome
NCT05753813Phase 1Recruiting
- Sponsor
- The Queen's Medical Center
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of potassium bitartrate in bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), sponsored by The Queen's Medical Center. Primary endpoints: Vaginal microbiome makeup at 60 days and Vulvovaginitis symptoms at 60 days. Started Dec 2023; status: recruiting.
02
Drugs
potassium bitartrate
03
Conditions
bacterial vaginosis (BV)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT05753813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753813.